New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lufax Holding Ltd (NYSE: LU) resulting from allegations that Lufax may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Lufax securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with misleading information regarding the expected results of their Phase 3 studies for setrusumab in Osteogenesis Imperfecta (OI), which ultimately did not meet their primary endpoints [5][6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information was revealed [6].

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”), of the important April 20, 2026 lead plaintiff deadline. SO WHAT: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...

Group 1 - A class action lawsuit has been filed on behalf of purchasers of common stock of Alight, Inc. (NYSE: ALIT) for the period between November 12, 2024, and February 18, 2026 [1] - Investors who purchased Alight common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Alight made false and misleading statements regarding its growth potential and financial stability, failing to disclose that it could not maintain its promised dividend [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4] - Investors interested in joining the class action can find more information through the Rosen Law Firm's website or by contacting them directly [3][6]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its product DCCR [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Soleno Therapeutics made false and misleading statements about the safety of DCCR, particularly concerning significant safety concerns related to excess fluid retention in clinical trial participants [5]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and securing over $438 million for investors in 2019 [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Banco Santander, S.A. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - The investigation is prompted by claims that Santander may have misled investors, which could lead to a class action lawsuit seeking recovery of investor losses [2]. - Investors who purchased Santander securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Market Impact - On February 27, 2026, Santander's American Depositary Shares (ADSs) fell by 4.48%, followed by a further decline of 3.2% on February 28, 2026, in response to concerns raised by the collapse of UK mortgage provider Market Financial Solutions Ltd [4]. Group 3: Context of the Investigation - The investigation is set against the backdrop of a broader concern in the financial industry regarding potential losses among banks, particularly in the private credit sector, following the collapse of a lesser-known mortgage lender [3].

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Picard Medical, Inc. (NYSE American: PMI) between September 2, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased Picard Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Kyndryl Holdings, Inc. securities between August 7, 2024, and February 9, 2026, about the April 13, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Kyndryl securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Kyndryl's financial statements were materially misstated, lacked adequate internal controls, and that the company would be unable to timely file its Quarterly Report for the quarter ended December 31, 2025 [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Camping World Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial health during the Class Period from April 29, 2025, to February 24, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Camping World overstated its ability to manage inventory and optimize profits through data analytics [5]. - It is alleged that the company misrepresented retail demand and failed to disclose the need for strict inventory management, which negatively impacted gross profit and margins [5]. - Defendants are accused of not ensuring accurate disclosures about the company's financial health and management of Selling, General & Administrative (SG&A) expenses [5]. Group 2: Investor Information - Investors who purchased Camping World securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by May 11, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation for allegedly making misleading statements regarding its U.S. Electrophysiology segment, leading to investor losses during the Class Period from July 23, 2025, to February 3, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Boston Scientific's management was aware that the growth rate of its U.S. Electrophysiology segment was unsustainable, yet they made positive statements to investors [5]. - Investors were surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026, which the lawsuit attributes to the misleading statements made by the company [5]. Group 2: Participation Information - Investors who purchased Boston Scientific common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].